요약정보
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
- Resource Type
- Academic Journal
- Authors
- Mkhize NN; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Yssel AEJ; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Kaldine H; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; van Dorsten RT; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; South African Medical Research Council Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences University of the Witwatersrand, Johannesburg, South Africa.; Woodward Davis AS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Beaume N; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Matten D; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Lambson B; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Modise T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Kgagudi P; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; York T; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Westfall DH; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Giorgi EE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Korber B; Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.; Anthony C; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Mapengo RE; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Bekker V; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Domin E; Department of Surgery, Duke University, Durham, North Carolina, United States of America.; Eaton A; Department of Surgery, Duke University, Durham, North Carolina, United States of America.; Deng W; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; DeCamp A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Gwashu-Nyangiwe A; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Thebus R; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Ndabambi N; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Mielke D; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Department of Surgery, Duke University, Durham, North Carolina, United States of America.; Mgodi N; University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.; Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Edupuganti S; Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, Georgia, United States of America.; Seaman MS; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.; Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.; Cohen MS; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North-Carolina, United States of America.; Hural J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Mullins JI; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Montefiori D; Department of Surgery, Duke University, Durham, North Carolina, United States of America.; Moore PL; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.; Williamson C; Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.; National Health Laboratory Service, Cape Town, South Africa.; Morris L; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.
- Source
- Publisher:
Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN:15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE - Subject
- Language
- English